121
文章数
5998
浏览数
储旻华

热衷收罗医药圈从研发到上市的各种“八卦”,然后基于事实和数据加以分析

聚焦患者需求≠叫停me-too | 研究院
储旻华 · 17天以前
研发客认为,市场对CDE文件做了过多解读。
Further information
观点·政策
SPAC热浪 | 投资观察
储旻华 · 19天以前
“炙烤”全球生命科学领域的资本运作模式。
Further information
投资月度
ADCs and Immuno-Oncology Therapies Attract Massive...
储旻华 · 21天以前
China Biotech Fundraising Tracker: May 2021
Further information
PharmaDJ
New Regulation Allows NDRL-Negotiated Drugs in Ret...
储旻华 · 21天以前
China Regulation Tracker: May 2021.
Further information
PharmaDJ
New CDE Guidelines Spur a Market Panic
储旻华 · 21天以前
Now, oncology is the hot field in drug development. Therefore, the CDE wants to guide clincial development through the document, emphasis the concept of clincial value-oriented, and implement the ICH PFDD guidelines through the document.
Further information
PharmaDJ
China Licensing Deals Tracker: May 2021
储旻华 · 25天以前
LianBio Acquires Three Potential FIC Therapies for Cancer and IBD.
Further information
PharmaDJ
China Market Approval Tracker: May 2021
储旻华 · 25天以前
The NMPA Grants Three Orphan Drugs Market Approval.
Further information
PharmaDJ
Key Takeaways from the CDE's 2020 Annual Drug Eval...
储旻华 · 25天以前
The amounts to a total increase of 32.67% from 2019 despite the pandemic.
Further information
PharmaDJ
China Biotech Fundraising Tracker: Apr 2021
储旻华 · 1月以前
Investors Pursuing More Opportunities With mRNA Technology.
Further information
PharmaDJ
China Regulation Tracker: Apr 2021
储旻华 · 1月以前
The COVID-19 Pandemic Sparks New Healthcare Reform Measures in China.
Further information
PharmaDJ
加载更多

个人信息

电子邮箱

chu.minhua@pharmadj.com

公司

研发客

职位

研究院院长

Copyright © 2016-2021 研发客.All Rights Reserved.   建议反馈: Support@PharmaDJ.com   备案/许可证编号:沪ICP备17054709号-1   联系电话:021 - 88194359
关于研发客 | 加入会员 | 联系我们| 知识产权声明